TWI481713B - 對中期因子之適體及其使用 - Google Patents

對中期因子之適體及其使用 Download PDF

Info

Publication number
TWI481713B
TWI481713B TW096142969A TW96142969A TWI481713B TW I481713 B TWI481713 B TW I481713B TW 096142969 A TW096142969 A TW 096142969A TW 96142969 A TW96142969 A TW 96142969A TW I481713 B TWI481713 B TW I481713B
Authority
TW
Taiwan
Prior art keywords
aptamer
seq
rna
group
midkine
Prior art date
Application number
TW096142969A
Other languages
English (en)
Chinese (zh)
Other versions
TW200831668A (en
Inventor
Shin Miyakawa
Masatoshi Fujiwara
Yoshikazu Nakamura
Takashi Matsui
Sadatoshi Sakuma
Original Assignee
Ribomic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribomic Inc filed Critical Ribomic Inc
Publication of TW200831668A publication Critical patent/TW200831668A/zh
Application granted granted Critical
Publication of TWI481713B publication Critical patent/TWI481713B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW096142969A 2006-11-14 2007-11-14 對中期因子之適體及其使用 TWI481713B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006308482 2006-11-14

Publications (2)

Publication Number Publication Date
TW200831668A TW200831668A (en) 2008-08-01
TWI481713B true TWI481713B (zh) 2015-04-21

Family

ID=39401681

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096142969A TWI481713B (zh) 2006-11-14 2007-11-14 對中期因子之適體及其使用

Country Status (27)

Country Link
US (1) US8080649B2 (pl)
EP (1) EP2096167B1 (pl)
JP (1) JP5190573B2 (pl)
KR (1) KR101516024B1 (pl)
CN (1) CN101573446B (pl)
AU (1) AU2007320401B2 (pl)
BR (1) BRPI0718913A2 (pl)
CA (1) CA2669523C (pl)
CO (1) CO6190535A2 (pl)
CY (1) CY1113679T1 (pl)
DK (1) DK2096167T3 (pl)
ES (1) ES2397715T3 (pl)
HK (1) HK1135729A1 (pl)
HR (1) HRP20130012T1 (pl)
IL (1) IL198705A (pl)
MX (1) MX2009005148A (pl)
MY (1) MY147374A (pl)
NO (1) NO342010B1 (pl)
NZ (1) NZ577396A (pl)
PL (1) PL2096167T3 (pl)
PT (1) PT2096167E (pl)
RU (1) RU2460794C2 (pl)
SI (1) SI2096167T1 (pl)
TW (1) TWI481713B (pl)
UA (1) UA100847C2 (pl)
WO (1) WO2008059877A1 (pl)
ZA (1) ZA200903562B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338517A1 (en) * 2005-11-14 2011-06-29 Ribomic Inc Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
WO2010035725A1 (ja) 2008-09-24 2010-04-01 株式会社リボミック Ｎｇｆに対するアプタマー及びその使用
JP6041373B2 (ja) * 2010-02-01 2016-12-07 Ｎｅｃソリューションイノベータ株式会社 ＴＮＦ−αに結合するアプタマー分子
ES2567270T3 (es) * 2010-03-24 2016-04-21 Ribomic Inc. Aptámero para FCN y utilización del mismo
SG190859A1 (en) 2010-12-20 2013-07-31 Colgate Palmolive Co Gelatin encapsulated oral care composition containing hydrophilic active, hydrophobic structuring agent and oil carrier
DK2762569T3 (en) * 2011-09-28 2018-08-27 Ribomic Inc NGF aptamer and its use.
JP6020888B2 (ja) * 2012-06-29 2016-11-02 国立大学法人名古屋大学 エポキシエイコサトリエン酸関連疾患の予防又は治療
WO2014080997A1 (ja) 2012-11-21 2014-05-30 株式会社リボミック ミッドカインに対するアプタマー及びその用途
RU2549704C1 (ru) * 2014-03-26 2015-04-27 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Рнк-аптамер, обладающий способностью узнавать характерные для рассеянного склероза аутоантитела
ES2886639T3 (es) 2016-07-01 2021-12-20 Somalogic Inc Oligonucleótidos que comprenden nucleósidos modificados
KR101985300B1 (ko) * 2016-07-19 2019-06-03 삼성전자주식회사 미드카인 저해제를 포함하는 뇌종양 치료 또는 예방용 약학 조성물
CN109536505B (zh) * 2018-12-07 2021-11-09 暨南大学 鬼臼毒素的核酸适配体及其应用
EP3894423A4 (en) * 2018-12-14 2022-10-12 Board of Regents, The University of Texas System DNA APTAMERS AND THEIR USE TO TREAT CANCER
JPWO2020241493A1 (pl) * 2019-05-24 2020-12-03

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1306435A (zh) * 1997-07-14 2001-08-01 明治乳业株式会社 含有midkine或其抑制剂作为活性成分的药剂
JP2004344008A (ja) * 2003-05-20 2004-12-09 Giichi Nakamura 翻訳開始因子ｅＩＦ４Ｅに結合するリガンド

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
JP3842304B2 (ja) 1992-10-08 2006-11-08 喬 村松 癌の診断、治療薬
ATE439146T1 (de) 1998-08-24 2009-08-15 Medical Therapies Ltd Zusammensetzungen zur vorbeugung und behandlung der artheriosklerose und der restenose nach ptca
US6858390B2 (en) * 1998-12-31 2005-02-22 Ingeneus Corporation Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes
JP2000354487A (ja) * 1999-06-15 2000-12-26 Takashi Muramatsu ミッドカイン受容体
EP1607102B1 (en) 2003-03-06 2017-01-18 Medical Therapies Limited Preventive for adhesion following abdominal surgery
JP4646070B2 (ja) 2003-03-27 2011-03-09 メディカル セラピーズ リミテッド 関節炎関連遺伝子及びこれの関節炎検査等への利用
JP2007297282A (ja) 2004-08-13 2007-11-15 Cell Signals Inc 子宮内膜症の発生の際にミッドカインによって起こる影響
JP2006141305A (ja) 2004-11-22 2006-06-08 Univ Of Tokyo 翻訳開始因子ｅＩＦ４Ｇに結合するリボ核酸
JP2006211905A (ja) 2005-02-01 2006-08-17 Univ Of Tokyo 腫瘍壊死因子受容体ファミリータンパク質に結合する核酸リガンド
JP2006308482A (ja) 2005-04-28 2006-11-09 Sanyo Electric Co Ltd 検出装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1306435A (zh) * 1997-07-14 2001-08-01 明治乳业株式会社 含有midkine或其抑制剂作为活性成分的药剂
JP2004344008A (ja) * 2003-05-20 2004-12-09 Giichi Nakamura 翻訳開始因子ｅＩＦ４Ｅに結合するリガンド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Edward N.Brody, Larry Gold，"Aptamers as therapeutic and diagnostic agents"，Reviews in Molecular Biotechnology，2000，Vol.74，page 5~13 *

Also Published As

Publication number Publication date
CA2669523A1 (en) 2008-05-22
BRPI0718913A2 (pt) 2013-12-10
EP2096167B1 (en) 2012-10-17
CA2669523C (en) 2016-06-21
EP2096167A4 (en) 2009-11-11
US8080649B2 (en) 2011-12-20
WO2008059877A1 (fr) 2008-05-22
CN101573446A (zh) 2009-11-04
US20100004432A1 (en) 2010-01-07
AU2007320401B2 (en) 2012-12-06
ES2397715T3 (es) 2013-03-08
JPWO2008059877A1 (ja) 2010-03-04
RU2009122476A (ru) 2010-12-20
KR101516024B1 (ko) 2015-04-29
CN101573446B (zh) 2013-07-17
TW200831668A (en) 2008-08-01
DK2096167T3 (da) 2013-02-04
NZ577396A (en) 2011-12-22
PT2096167E (pt) 2013-01-25
RU2460794C2 (ru) 2012-09-10
CO6190535A2 (es) 2010-08-19
EP2096167A1 (en) 2009-09-02
UA100847C2 (uk) 2013-02-11
HK1135729A1 (en) 2010-06-11
NO342010B1 (no) 2018-03-12
ZA200903562B (en) 2010-07-28
KR20090097879A (ko) 2009-09-16
MY147374A (en) 2012-11-30
MX2009005148A (es) 2009-08-24
CY1113679T1 (el) 2016-06-22
AU2007320401A1 (en) 2008-05-22
IL198705A (en) 2014-11-30
JP5190573B2 (ja) 2013-04-24
HRP20130012T1 (hr) 2013-01-31
NO20092280L (no) 2009-08-14
IL198705A0 (en) 2011-08-01
PL2096167T3 (pl) 2013-03-29
SI2096167T1 (sl) 2013-02-28

Similar Documents

Publication Publication Date Title
TWI481713B (zh) 對中期因子之適體及其使用
JP6118724B2 (ja) Ｎｇｆに対するアプタマー及びその用途
JP5810356B2 (ja) キマーゼに対するアプタマー及びその使用
JP5899550B2 (ja) Ｆｇｆ２に対するアプタマー及びその使用
WO2013186857A1 (ja) Ｆｇｆ２に対するアプタマー及びその使用
JP5602020B2 (ja) Ｎｇｆに対するアプタマー及びその使用
JPWO2009063998A1 (ja) 疎水性物質付加核酸及びその使用
JP6634554B2 (ja) Ｆｇｆ２に対するアプタマー及びその使用
KR101807590B1 (ko) Il-17에 대한 앱타머 및 그 사용
JP7264487B2 (ja) キマーゼに対するアプタマー及びその使用
WO2021006305A1 (ja) ＴＧＦ－β１に対するアプタマー及びその使用
WO2011024955A1 (ja) ＴＧＦ－βＩＩ型受容体に結合する核酸およびその使用

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees